| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBY | Common Stock | Options Exercise | +858 | +100% | 1.72K | May 11, 2023 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBY | Restricted Stock Units | Options Exercise | $0 | -858 | -100% | $0.00* | 0 | May 11, 2023 | Common Stock | 858 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | On November 15, 2022, NovaBay Pharmaceuticals, Inc. effected a 1-for-35 reverse stock split of its common stock, which is reflected in the number of shares. |
| F2 | Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vested on the one year anniversary of the date of grant. |